Savara Q4 net loss widens as expenses rise

Overview

• US rare disease drug developer's Q4 net loss widened yr/yr as expenses rose

• General and administrative expenses increased due to workforce expansion and commercial planning

• Company achieved key regulatory milestones for MOLBREEVI in US and Europe

Outlook

• Savara expects FDA PDUFA decision on MOLBREEVI by August 22, 2026

Result Drivers

• REGULATORY COSTS - Higher research and development expenses were primarily due to regulatory affairs and quality assurance activities related to the MOLBREEVI BLA submission

• COMMERCIAL PLANNING - General and administrative expenses rose due to workforce expansion and commercial activities ahead of potential MOLBREEVI launch

Company press release: ID:nBw2mblyra

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the biotechnology & medical research peer group is "buy"

• Wall Street's median 12-month price target for Savara Inc is $10.25, about 92.7% above its March 12 closing price of $5.32

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.